Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Henry G. Smith, Dirk J. Grünhagen, Andrew J. Hayes, Robin L. Jones, F. van Coevorden, E.A. Huis in ’t Veld, Cees Verhoef, W.J. van Houdt, A.C.J. van Akkooi
Publikováno v:
European Journal of Cancer, 85, 114-121. Elsevier Ltd.
BACKGROUND: Angiosarcomas are rare and aggressive soft-tissue sarcomas. The only potential curative treatment is complete surgical excision. This study reports the outcome of isolated limb perfusion (ILP) with high-dose melphalan and tumour necrosis
Autor:
Djura Piersma, Margreet G. Franken, Geke A. P. Hospers, Jan Willem B. de Groot, Maureen J.B. Aarts, Rozemarijn S. van Rijn, B Leeneman, Marieke W. J. Louwman, Ellen Kapiteijn, Michel W.J.M. Wouters, Alfons J.M. van den Eertwegh, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Hans Gelderblom, John B. A. G. Haanen, Albert J. ten Tije, Gerard Groenewegen, Gerard Vreugdenhil, M Schouwenburg, Mathilde C. Cardous-Ubbink, A Jochems, Carin A. Uyl-de Groot, Rutger H. T. Koornstra, Wim H. J. Kruit
Publikováno v:
European Journal of Cancer, 72, 156-165. ELSEVIER SCI LTD
Jochems, A, Schouwenburg, M G, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, Gelderblom, H, Uyl-de Groot, C A, Aarts, M J B, van den Berkmortel, F W P J, Blokx, W A M, Cardous-Ubbink, M C, Groenewegen, G, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W, Piersma, D, van Rijn, R S, Ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2016, ' Dutch Melanoma Treatment Registry : Quality assurance in the care of patients with metastatic melanoma in the Netherlands ', European Journal of Cancer, vol. 72, pp. 156-165 . https://doi.org/10.1016/j.ejca.2016.11.021
European Journal of Cancer, 72, 156-165
European Journal of Cancer, 72, 156. Elsevier Limited
European Journal of Cancer, 72, 156-165. Elsevier Ltd.
European Journal of Cancer, 72, pp. 156-165
European Journal of Cancer, 72, 156-165. Pergamon
Jochems, A, Schouwenburg, M G, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, Gelderblom, H, Uyl-de Groot, C A, Aarts, M J B, van den Berkmortel, F W P J, Blokx, W A M, Cardous-Ubbink, M C, Groenewegen, G, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W, Piersma, D, van Rijn, R S, Ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2016, ' Dutch Melanoma Treatment Registry : Quality assurance in the care of patients with metastatic melanoma in the Netherlands ', European Journal of Cancer, vol. 72, pp. 156-165 . https://doi.org/10.1016/j.ejca.2016.11.021
European Journal of Cancer, 72, 156-165
European Journal of Cancer, 72, 156. Elsevier Limited
European Journal of Cancer, 72, 156-165. Elsevier Ltd.
European Journal of Cancer, 72, pp. 156-165
European Journal of Cancer, 72, 156-165. Pergamon
Contains fulltext : 174807.pdf (Publisher’s version ) (Closed access) BACKGROUND: In recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and mitogen-activated protein (MAP) kinase
Autor:
Eric P. van der Stok, Cornelis J. A. Punt, Leonie J. M. Mekenkamp, Cornelis Verhoef, Bastiaan Wiering, Miriam Koopman, Jannemarie A. M. de Ridder, Johannes H. W. de Wilt
Publikováno v:
European Journal of Cancer, 59, 13-21. Elsevier Ltd.
European Journal of Cancer, 59, 13-21
European journal of cancer (Oxford, England, 59, 13-21. Elsevier Limited
European Journal of Cancer, 59, 13. Elsevier Limited
European Journal of Cancer, 59, pp. 13-21
European Journal of Cancer, 59, 13-21
European journal of cancer (Oxford, England, 59, 13-21. Elsevier Limited
European Journal of Cancer, 59, 13. Elsevier Limited
European Journal of Cancer, 59, pp. 13-21
Item does not contain fulltext OBJECTIVE: To evaluate and compare the overall survival (OS) in case-matched patient groups treated either with systemic therapy or surgery for colorectal liver metastases (CRLM). METHODS: Patients with CRLM, without ex
Autor:
Enrique Aranda, García Teijido P, Jose Ignacio Martin-Valades, González Flores E, A. Viudez, A. Gomez, M.J. Safont, E. Falcó, Ma García Tapiador A, Manuel Benavides, Ma López Muñoz A, Javier Sastre, Jose Luis Manzano, Sánchez Ruiz A, Margarita Reboredo, Carmen Guillén-Ponce, Cristina Grávalos, Julia Alcaide, Barrajón E, P. García-Alfonso, Francisca Vázquez Rivera, Rafael López, Eduardo Díaz-Rubio, T. García, Marta Navalón, Cárdenas N, Méndez Ureña M
Publikováno v:
European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
EUROPEAN JOURNAL OF CANCER
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
EUROPEAN JOURNAL OF CANCER
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Background: This multicentre, randomised, and phase II study evaluated mFOL-FOX+cetuximab followed by maintenance mFOLFOX+cetuximab or single-agent cetuximab in metastatic colorectal cancer (mCRC) patients (NCT01161316). Patients and methods: Previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fcf4dc14bf673a1e87f764bccfb30a7
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5481
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5481
Autor:
Linda Dirven, Martin J.B. Taphoorn, Martin J. van den Bent, Nelly van der Meer, Maaike J. Vos, Jaap C. Reijneveld, Jacoline E C Bromberg, Filip de Vos, Marion Smits, Bronno van der Holt, Monique Hanse, Andrew Bottomley, Aja Otten, Walter Taal, Laurens V. Beerepoot, Annemiek M E Walenkamp
Publikováno v:
European Journal of Cancer, 51(10), 1321. Elsevier Limited
European journal of cancer (Oxford, England, 51(10), 1321-1330. Elsevier Limited
European Journal of Cancer, 51(10), 1321-1330. Elsevier Ltd.
European Journal of Cancer, 51(10), 1321-1330. Pergamon
European Journal of Cancer, 51(10), 1321-1330. ELSEVIER SCI LTD
Dirven, L, van den Bent, M J, Bottomley, A, van der Meer, N, van der Holt, B, Vos, M J, Walenkamp, A M E, Beerepoot, L V, Hanse, M C J, Reijneveld, J C, Otten, A, de Vos, F Y F L, Smits, M, Bromberg, J E C, Taal, W & Taphoorn, M J B 2015, ' The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial ', European Journal of Cancer, vol. 51, no. 10, pp. 1321-1330 . https://doi.org/10.1016/j.ejca.2015.03.025
European journal of cancer (Oxford, England, 51(10), 1321-1330. Elsevier Limited
European Journal of Cancer, 51(10), 1321-1330. Elsevier Ltd.
European Journal of Cancer, 51(10), 1321-1330. Pergamon
European Journal of Cancer, 51(10), 1321-1330. ELSEVIER SCI LTD
Dirven, L, van den Bent, M J, Bottomley, A, van der Meer, N, van der Holt, B, Vos, M J, Walenkamp, A M E, Beerepoot, L V, Hanse, M C J, Reijneveld, J C, Otten, A, de Vos, F Y F L, Smits, M, Bromberg, J E C, Taal, W & Taphoorn, M J B 2015, ' The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial ', European Journal of Cancer, vol. 51, no. 10, pp. 1321-1330 . https://doi.org/10.1016/j.ejca.2015.03.025
Background: The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with recurrent glioblastoma, showed that the 9-month overall survival rate was most promising in th
Autor:
Montse Batlle, Christelle Ferra, Marc Sorigue, Miriam Moreno, Gladys Ibarra, Alberto Pineda, Gustavo Tapia, Susanna Vives, Evarist Feliu, Juan-Manuel Sancho, Josep-Maria Ribera, David Lopez, Olga García
Publikováno v:
Leukemia Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2b6e988ccd85fcdc8b0fae9ad76e17c
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6242
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6242
Autor:
Jerzy, Hildebrand, Thierry, Gorlia, Johan M, Kros, Dénes, Afra, Marc, Frenay, Antonio, Omuro, Roger, Stupp, Denis, Lacombe, Anouk, Allgeier, Martin J, van den Bent, J, Bravo Marques
Publikováno v:
European Journal of Cancer, 44(9), 1210-1216. Elsevier Ltd.
Background: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overa
Autor:
Jaap Verweij, E.G.E. de Vries, Robert A. Carr, Dra Uges, R. Hoekstra, F.Y.F.L. de Vos, Ferry A.L.M. Eskens, Jourik A. Gietema, Raymond A. Knight, Rod A. Humerickhouse
Publikováno v:
European Journal of Cancer, 42(4), 467-472. Elsevier Ltd.
European Journal of Cancer, 42(4), 467-472. ELSEVIER SCI LTD
European Journal of Cancer, 42(4), 467-472. ELSEVIER SCI LTD
We performed a phase I study with the thrombospondin-l-mimetic angiogenesis inhibitor ABT-510 combined with 5-fluorouracil and leucovorin (5-FU/LV) to determine safety profile and assess pharmacokinetic interactions. Patients with advanced solid mali
Autor:
Jaap Verweij, R. de Vries, K. Nooter, Ferry A.L.M. Eskens, P.A. Palmer, Elisabeth Brouwer, L. van Zuylen, C.J. Bol, Alex Sparreboom, A. van der Gaast
Publikováno v:
European Journal of Cancer, 38, 1090-1099. Elsevier Ltd.
Recently, a study of docetaxel in combination with the new orally administered P-glycoprotein (P-gp) inhibitor R101933 showed that this combination was feasible. However, due to the low oral bioavailability of R101933 and high interpatient variabilit